评价含贝伐珠单抗辅助治疗三阴性早期乳腺癌的随机III期BEATRICE试验的最终疗效和更新安全性结果
BEATRICE试验最终分析显示,中位随访56个月,早期三阴性乳腺癌患者化疗联合贝伐珠单抗与单纯化疗相比,总生存无统计学显著差异(HR 0.93,95%CI 0.74-1.17;P=0.52),5年OS率两组均为88%。更新无侵袭性疾病生存结果与主要分析一致,5年IDFS率化疗组77% vs 贝伐珠单抗组80%。
要点
- 中位随访56个月,总人群OS无显著差异(HR 0.93,95%CI 0.74-1.17;P=0.52)。
- 5年OS率两组均为88%(95%CI 86-90%)。
- 5年IDFS率化疗组77% vs 贝伐珠单抗组80%。
核心结论
- 最终OS结果未显示贝伐珠单抗对早期三阴性乳腺癌有显著获益。
- 两组晚期毒性均少见。
- 5年OS和IDFS率提示三阴性乳腺癌预后优于既往认识。
研究设计与样本
- 开放标签随机III期BEATRICE试验,纳入经中心确认的可手术原发浸润性三阴性乳腺癌(pT1a-pT3)患者。
- 患者术后1:1随机接受≥4周期化疗或化疗联合1年贝伐珠单抗(5 mg/kg/周等效剂量)。
- 分层因素为淋巴结状态、所选化疗方案、激素受体状态和手术类型。
- 主要终点为无侵袭性疾病生存(IDFS;既往已报告),次要终点包括总生存(OS)和安全性。
- 共2591例随机患者,中位随访56个月。
主要发现
- 总人群OS无统计学显著差异(HR 0.93,95%CI 0.74-1.17;P=0.52),预设亚组亦无显著差异。
- 5年OS率两组均为88%(95%CI 86-90%)。
- 更新IDFS结果与主要IDFS分析一致。
- 5年IDFS率化疗组77%(95%CI 75-79%)vs 贝伐珠单抗组80%(95%CI 77-82%)。
- 从首次研究给药后18个月至研究结束,两组新发≥3级不良事件发生率分别为4.6%和4.5%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this analysis was to assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast cancer (TNBC). METHODS: Patients eligible for the open-label randomized phase III BEATRICE trial had centrally confirmed triple-negative operable primary invasive breast cancer (pT1a-pT3). Investigators selected anthracycline- and/or taxane-based chemotherapy for each patient. After definitive surgery, patients were randomized 1:1 to receive ≥4 cycles of chemotherapy alone or with 1 year of bevacizumab (5 mg/kg/week equivalent). Stratification factors were nodal status, selected chemotherapy, hormone receptor status, and type of surgery. The primary end point was invasive disease-free survival (IDFS; previously reported). Secondary outcome measures included overall survival (OS) and safety. RESULTS: After 56 months' median follow-up, 293 of 2591 randomized patients had died. There was no statistically significant difference in OS between treatment arms in either the total population (hazard ratio 0.93, 95% confidence interval [CI] 0.74-1.17; P = 0.52) or pre-specified subgroups. The 5-year OS rate was 88% (95% CI 86-90%) in both treatment arms. Updated IDFS results were consistent with the primary IDFS analysis. Five-year IDFS rates were 77% (95% CI 75-79%) with chemotherapy alone versus 80% (95% CI 77-82%) with bevacizumab. From 18 months after first study dose to study end, new grade ≥3 adverse events occurred in 4.6% and 4.5% of patients in the two arms, respectively. CONCLUSION: Final OS results showed no significant benefit from bevacizumab therapy for early TNBC. Late-onset toxicities were rare in both groups. Five-year OS and IDFS rates suggest that the prognosis for patients with TNBC is better than previously thought. CLINICALTRIALS.GOV: NCT00528567.
引用
- Bell R, Brown J, Parmar M, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol. 2017. PMID: 27993816. doi:10.1093/annonc/mdw665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。